NAD+ and NMN sit on the same metabolic pathway — NMN is one step away from becoming NAD+, the coenzyme every cell uses for energy metabolism and DNA repair. The comparison is really about routes: take the precursor orally and let cells convert it, or supply the coenzyme itself directly. Each route has a different evidence profile, and neither has the clinical-outcome data the longevity conversation sometimes implies.
| Attribute | NAD+ | NMN |
|---|---|---|
| What it is | The coenzyme itself (nicotinamide adenine dinucleotide) | A direct precursor (nicotinamide mononucleotide), converted to NAD+ in cells |
| Typical route | Subcutaneous / IV in practitioner settings | Oral supplement |
| Human evidence | Thin formal trial record for injectable NAD+ itself | Small oral trials consistently show raised blood NAD+ levels, safely |
| Outcome data | Biomarker and anecdotal reports; no completed clinical programme | Biomarker changes more reliable than clinical endpoints so far |
| Regulatory picture | Not an approved medicine; no authorised indication | Contested supplement status in the US (FDA drug-preclusion); EU novel-food rules apply |
| Bioavailability question | Bypasses digestion entirely | Oral absorption and conversion efficiency still actively debated |
| In the Body Pharm catalogue | Yes (NAD+ 1000 pen) | No |
Cells make NAD+ continuously, mostly by recycling nicotinamide through the salvage pathway — NMN is the last intermediate in that route. Oral NMN asks the gut and liver to absorb and convert it; injectable NAD+ skips the conversion question by supplying the finished coenzyme. The trade-off runs the other way on evidence: the oral-precursor route has more human studies behind it, while direct NAD+ administration has the cleaner delivery logic but the thinner formal record.
Precursor trials (NMN and the related nicotinamide riboside) reliably raise blood NAD+ levels and look safe over study durations. What they have not yet shown consistently is hard clinical outcomes — the endpoint data lags the biomarker data. Injectable NAD+ has even less formal trial coverage; its use in wellness and practitioner settings runs well ahead of its published evidence.
NMN’s status is contested: the US FDA has taken the position that NMN is precluded from sale as a dietary supplement because it was studied as a drug candidate, and in the EU it falls under novel-food authorisation rules. NAD+ itself is not an approved medicine anywhere and has no authorised injectable indication. Neither compound’s regulatory story matches the confidence of its marketing.
No head-to-head human trial answers this. Oral NMN has more evidence that it raises NAD+ levels; injectable NAD+ has the more direct delivery route but a thinner trial record. Neither has demonstrated superior clinical outcomes.
The research rationale is bypassing oral absorption and conversion, which remain debated for NMN. That is a delivery argument, not an outcomes claim — the formal evidence for injectable NAD+ is limited.
Not banned, but contested: the US FDA considers it precluded from dietary-supplement status, and in the EU it requires novel-food authorisation. Enforcement and availability vary by market.
No. Lifespan extension has been shown in some animal models for NAD+-boosting strategies, but no human lifespan or healthspan outcome has been demonstrated for either compound.
This page is educational and intended for research and informational use only. It is not medical advice, a treatment recommendation, or dosing guidance, and it makes no promises about outcomes. Where a compound has held a marketing authorisation, approved medicines are supplied only through licensed pharmacies with a prescription. Body Pharm EU supplies research-grade materials for laboratory use, not approved medicines, and nothing here should be read as a substitute for advice from a qualified healthcare professional.
We use cookies for analytics and marketing to improve your experience. You can accept or reject non-essential cookies. Privacy Policy